108 related articles for article (PubMed ID: 17802728)
1. [Pathophysiology of and therapy for primary myelofibrosis].
Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1724-32. PubMed ID: 17802728
[No Abstract] [Full Text] [Related]
2. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
[No Abstract] [Full Text] [Related]
3. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
4. [Molecular pathology and treatment for primary myelofibrosis].
Kitanaka A; Shimoda K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():321-5. PubMed ID: 23133975
[No Abstract] [Full Text] [Related]
5. Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
Wardhana ; Datau EA; Rotty LW; Haroen H
Acta Med Indones; 2011 Oct; 43(4):252-9. PubMed ID: 22156358
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Rondelli D
Haematologica; 2008 Oct; 93(10):1449-50. PubMed ID: 18827262
[No Abstract] [Full Text] [Related]
7. Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
TAHARA K; YOKOHAMA A; HANDA H; SAITOH T; UCHIUMI H; SEKIGAMI T; TOYAMA K; MAWATARI M; OSAKI Y; MATSUSHIMA T; KARASAWA M; MURAKAMI H; TSUKAMOTO N; NOJIMA Y
Rinsho Ketsueki; 2009 Nov; 50(11):1630-4. PubMed ID: 20009439
[TBL] [Abstract][Full Text] [Related]
8. Modern management of myelofibrosis.
Cervantes F
Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
[TBL] [Abstract][Full Text] [Related]
9. From palliation to epigenetic therapy in myelofibrosis.
Rambaldi A; Barbui T; Barosi G
Hematology Am Soc Hematol Educ Program; 2008; ():83-91. PubMed ID: 19074063
[TBL] [Abstract][Full Text] [Related]
10. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
11. Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation.
Rumi E; Passamonti F; Arcaini L; Bernasconi P; Elena C; Pietra D; Brisci A; Arbustini E; Cazzola M; Lazzarino M
Bone Marrow Transplant; 2010 Apr; 45(4):798-800. PubMed ID: 19734947
[No Abstract] [Full Text] [Related]
12. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy.
Siebolts U; Lange T; Niederwieser D; Wickenhauser C
J Clin Pathol; 2010 Apr; 63(4):370-2. PubMed ID: 20354212
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
Tefferi A
Bone Marrow Transplant; 2010 Mar; 45(3):419-21. PubMed ID: 20216545
[No Abstract] [Full Text] [Related]
14. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
15. Are we altering the natural history of primary myelofibrosis?
Savona MR
Leuk Res; 2014 Sep; 38(9):1004-12. PubMed ID: 24931396
[TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
[No Abstract] [Full Text] [Related]
17. When to initiate treatment in myelofibrosis.
Harrison C
Clin Adv Hematol Oncol; 2016 Nov; 14(11):934-937. PubMed ID: 27930645
[No Abstract] [Full Text] [Related]
18. Allogeneic stem cell transplantation for myelofibrosis in 2012.
McLornan DP; Mead AJ; Jackson G; Harrison CN
Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis with myeloid metaplasia.
Guardiola P; Anderson JE; Gluckman E
N Engl J Med; 2000 Aug; 343(9):659; author reply 659-60. PubMed ID: 10979803
[No Abstract] [Full Text] [Related]
20. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N; Alchalby H; Klyuchnikov E; Badbaran A; Hildebrandt Y; Ayuk F; Bacher U; Bock O; Kvasnicka M; Fehse B; Zander A
Blood; 2009 Feb; 113(8):1866-8. PubMed ID: 19228938
[No Abstract] [Full Text] [Related]
[Next] [New Search]
